Scarica l'app Stockscreener
45.56
0.70%
0.315
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Alkermes Plc Borsa (ALKS) Ultime notizie
Acute Agitation And Aggression Treatment Market Size To Reach $8.7 Billion By 2030 At A CAGR Of 7.5% - EIN News
Narcolepsy Pipeline Outlook 2026: Oral, Injectable, and Novel Delivery Candidates Advancing Through Clinical Trials | Novartis, Shionogi Inc., Takeda, Avadel Pharma, Harmony Biosciences, Jazz Pharma - StreetInsider
Earnings Preview: Tarsus Pharmaceuticals, Inc. (TARS) Q3 Earnings Expected to Decline - Zacks Investment Research
Alkermes plc (ALKS) Options ChainYahoo Finance - Yahoo! Finance Canada
HRMY Stock Gains 27.6% in Six Months: Is There More Room for Growth? - Zacks Investment Research
4 CNS Drug Stocks Worth Watching This World Mental Health Day - Zacks Investment Research
Why Baird Sees Promising Growth Potential in Alkermes plc (ALKS) - Yahoo Finance
Global Substance Use Disorder Treatment Market Analysis and Forecast to 2030 | Long-Acting Therapies, Telemedicine, and Drug Innovation Drive Growth - GlobeNewswire Inc.
Alkermes plc (ALKS) Stock Price, News, Quote & History - Yahoo! Finance Canada
Alkermes Posts Positive Data From Phase I ADHD Study on ALKS 7290 - Zacks Investment Research
Form 8K Alkermes plc. For: 21 September By Investing.com - Investing.com Canada
REGBlackRock GroupSAR 6ALKERMES PLC - TradingView
Form 8K Alkermes plc. For: 16 September By Investing.com - Investing.com Nigeria
New Alkermes (NASDAQ: ALKS) director to get $600,000 in stock awards - Stock Titan
Alkermes Announces Appointment of Anne C. Whitaker to Board of Directors - PA Media
Alkermes Announces Appointment of Anne C. Whitaker to Board of Directors - Financial Times
Alkermes Announces Appointment of Anne C. Whitaker to Board of Directors - Alkermes
Alkermes: A Slow-Burning Buy Prospect On Orexin-Agonist Promise (NASDAQ:ALKS) - Seeking Alpha
Alkermes upgraded to Buy on strong growth, new drug launches, and promising pipeline in CNS disorders. - Pluang
Alkermes Announces Launch of 9th Annual Alkermes Pathways Research Awards® Program - Business Wire
After two decades at Alkermes, a biotech CFO joins Tortugas’ board - Stock Titan
Responsive Playbooks and the ALKS Inflection - Stock Traders Daily
Alkermes Plc (ALKS) Investor Outlook: Strong Buy Ratings And 21% Potential Upside - DirectorsTalk Interviews
Should Alkermes’ (ALKS) Narcolepsy Data And Phase 3 Pivot Reshape Investor Views On Its Pipeline? - simplywall.st
Should Alkermes’ (ALKS) Narcolepsy Data And Phase 3 Pivot Reshape Investor Views On Its Pipeline? - simplywall.st
Alkermes (ALKS) EVP and CLO David Gaffin Sells 2,034 Shares - GuruFocus
Alkermes (NASDAQ: ALKS) officer readies stock sale - Stock Titan
Alkermes (NASDAQ: ALKS) exec lines up $423K stock sale - Stock Titan
Mizuho reiterates Alkermes stock rating ahead of ADHD trial data By Investing.com - Investing.com South Africa
Mizuho reiterates Alkermes stock rating ahead of ADHD trial data By Investing.com - Investing.com Australia
Mizuho reiterates Alkermes stock rating ahead of ADHD trial data - Investing.com
Mizuho reiterates Alkermes stock rating ahead of ADHD trial data - Investing.com India
Alkermes plc (ALKS) Stock Analysis: Exploring an 18% Potential Upside with a Solid Revenue Growth Story - DirectorsTalk Interviews
Discipline and Rules-Based Execution in ALKS Response - Stock Traders Daily
Alkermes Chief Commercial Officer Sells 7,576 Shares for $373,000 - The Globe and Mail
Alkermes Chief Commercial Officer Sells 7,576 Shares for $373,000 - The Motley Fool
Alkermes Executive Sells 7,576 Shares, Reducing Holdings - Intellectia AI
Alkermes PLC (ALKS) Stock Down 3.1% but Still Overvalued -- GF S - GuruFocus
Rising Star: Goodwin's Heath Ingram - Law360
Rising Star: Goodwin's Heath Ingram - Law360
ALKS Looks 52.4% Overvalued on GF Value™ Amid New Drug Pricing D - GuruFocus
Alkermes narcolepsy drug shows positive phase 2 trial results By Investing.com - Investing.com Nigeria
Alkermes narcolepsy drug shows positive phase 2 trial results By Investing.com - Investing.com Canada
The Lancet Neurology Publishes Data From Alkermes’ Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 1 - Yahoo Finance
Alkermes’ investigational narcolepsy treatment improved wakefulness at every dose - Stock Titan
Alkermes PLC (ALKS) Shares Fall 4.4% -- What GF Score of 64 Tells Investors - GuruFocus
Alkermes ends Amneal VIVITROL supply pact without penalties - scanx.trade
Alkermes reports phase 2 Vibrance-2 data; alixorexton meets dual primary endpoints in narcolepsy type 2 - scanx.trade
Alkermes (ALKS) Shares: Posts a 3.31% Loss to $48.52 for the Current Session; Current Setup: Traders Can Monitor the $46.09-$50.95 Range for the Current SessionStatistical Arbitrage - vinanet.vn
Q2 2026 Alkermes Plc Earnings Call Transcript - GuruFocus
0.38%
0.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):